Related Experiment Video
Updated: Feb 25, 2026
07:01
A Pediatric Concussion Model in Mice: Closed Head Injury with Long-Term Disorders (CHILD)
Published on: February 7, 2025
930
Methodological and Ethical Issues in Pediatric Medication Safety Research.
Delesha Carpenter1, Daniel Gonzalez2, George Retsch-Bogart3,4,5
1Division of Pharmaceutical Outcomes and Policy, dmcarpenter@unc.edu.
Pediatrics
|August 6, 2017
Summary
This conference summary highlights challenges and solutions for pediatric medication safety research. It focuses on improving drug development, comparative research, and patient engagement to enhance children's health outcomes.
Area of Science:
- Pediatric Pharmacology
- Clinical Research Ethics
- Translational Science
Background:
- Pediatric medication safety research faces significant methodological and ethical hurdles.
- Expert consensus identified key challenges in drug development, comparative effectiveness, and patient engagement for children.
- Improving pediatric medication safety is crucial for advancing child health outcomes.
Purpose of the Study:
- To summarize challenges and propose innovative, ethical methodologies for pediatric medication safety research.
- To identify opportunities for advancing the field of pediatric drug safety.
- To improve the health of children through better medication research practices.
Main Methods:
- Convening a multidisciplinary expert conference (PharmSci 2016) at the Eshelman School of Pharmacy.
- Gathering diverse perspectives from regulatory bodies (US Food and Drug Administration), healthcare institutions (children's hospitals), and academia.
- Synthesizing discussions on five key areas: drug development, comparative effectiveness, child/parent engagement, communication, and outcome assessment.
Main Results:
- Identified critical challenges in pediatric drug development and clinical trials.
- Highlighted the need for effective comparative effectiveness research in pediatric populations.
- Emphasized the importance of child and parent engagement in study design and execution.
- Stressed the necessity of improved communication strategies with children and parents.
- Addressed methods for assessing child-reported outcomes and adverse drug events.
Conclusions:
- Innovative and ethically sound methodologies are essential to overcome current challenges in pediatric medication safety research.
- Enhanced child and parent engagement, improved communication, and robust outcome assessments are key to advancing the field.
- Addressing these issues will lead to improved medication safety and better health outcomes for children.
More Related Videos
Related Concept Videos
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
359
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
359
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
329
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
329
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
286
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
286
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
375
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
375
01:26Pharmaceutical Poisoning: Potential Scenarios
37
Pharmaceutical poisoning can occur through various channels, impacting an estimated 2 million hospitalized patients in the U.S. annually with serious adverse drug responses. These scenarios encompass both therapeutic uses, such as drug toxicity, where even standard dosages can lead to severe central nervous system depression, and non-therapeutic exposures, including accidental ingestion by children, and environmental and occupational exposures.Unintentional poisonings often involve exploratory...
37
01:29Drug Dosing: Infants and Children
388
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
388